Ligand Pharmaceuticals Inc - Class B
Research Ligand Pharmaceuticals Inc - Class B (LGND) on Bullrun: market cap USD 6.24B, P/E 33.3. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerLGND
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 6.24B
- P/E33.3
- Financial periodQ2 2026
- RevenueUSD 63.69M
- Net incomeUSD 48.51M
- Free cash flowUSD 21.35M
- Gross margin95.0%
Valuation Snapshot
latest market cap is USD 6.24B; P/E is 33.3.
Peer valuation comparison
Latest P/E is 33.27x versus a Healthcare sector median of 24.6x (35.2% above).
Latest P/E is 33.27x versus a United States median of 23.85x (39.5% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 268.09M | USD 124.45M | USD 48.91M | 94.6% | 6.13 | USD 174.93M | USD 451.49M | USD 1.02B |
| FY2024 | USD 167.13M | -USD 4.03M | USD 95.23M | 93.4% | -0.22 | USD 72.31M | USD 7.08M | USD 830.44M |
| FY2023 | USD 131.31M | USD 52.15M | USD 46.06M | 92.0% | 2.94 | USD 22.95M | USD 6.17M | USD 700.91M |
| FY2022 | USD 196.25M | -USD 33.36M | USD 119.93M | 73.1% | -1.98 | USD 45.01M | USD 87.75M | USD 597.49M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-12 | USD 6.24B | 33.3 | n/a | n/a |
| 2025 | 2025-12-31 | USD 3.74B | 32.4 | n/a | n/a |
| 2024 | 2024-12-31 | USD 2.05B | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 1.25B | 85.0 | n/a | n/a |
| 2022 | 2022-12-30 | USD 1.13B | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 1.62B | 29.0 | n/a | n/a |
About Ligand Pharmaceuticals Inc - Class B
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma.
ETFs that hold Ligand Pharmaceuticals Inc - Class B
Ligand Pharmaceuticals Inc - Class B is one of the ten largest holdings of 2 ETFs that investors in Europe can buy, most traded first:
| ETF | Weight | TER |
|---|---|---|
| L&G Pharma Breakthrough UCITS ETF | 3.59% | 0.49% |
| Jupiter Origin Global Smaller Companies Active UCITS ETF USD Acc | 1.18% | 0.45% |
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Ligand Pharmaceuticals Inc - Class B's market cap?
Ligand Pharmaceuticals Inc - Class B's market capitalization is USD 6.24B.
What is Ligand Pharmaceuticals Inc - Class B's P/E ratio?
Ligand Pharmaceuticals Inc - Class B's price-to-earnings (P/E) ratio is 33.3.
What does Ligand Pharmaceuticals Inc - Class B do?
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma.